Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EX-99.1 2 ptn_ex991.htm PRESS RELEASE EXHIBIT 99.1 CRANBURY, NJ – May 15, 2024 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third quarter ended March 31, 2024. "Study results of our successful Phase 3 M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (State ...

Fiscal Third Quarter Ended March 31, 2024 Business Highlights and Recent Updates Anti-Inflammatory / Autoimmune Programs (melanocortin receptor agonists) Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment Period Rapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Signif ...

CORPORATE PRESENTATION February 2024 Stephen T. Wills, CPA/MST CFO / COO 2 3 Vyleesi®(bremelanotide) Hypoactive Sexual Desire Disorder * These programs are planned but dependent on funding. Ophthalmology MCr Programs Conjunctiva/Cornea/Ocular surface • Glaucoma | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------- ...

Palatin Technologies, Inc. (NYSE:PTN) Q2 2024 Earnings Conference Call February 15, 2024 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Higgins - Ladenburg Thalmann John Newman - Canaccord Operator Greetings. Welcome to Palatin’s Second Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. | Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registe ...

Palatin Technologies, Inc. (NYSE:PTN) Q1 2024 Earnings Conference Call November 14, 2023 11:00 AM ET Company Participants Carl Spana – President and Chief Executive Officer Steve Wills – Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Operator Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4078884 (State or other jurisdiction of FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ...

Palatin Technologies, Inc. (NYSE:PTN) Q4 2023 Earnings Conference Call September 28, 2023 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co., LLC Michael Higgins - Ladenburg Thalmann & Co. Inc. Operator Greetings, and welcome to Palatin's Fourth Quarter and Fiscal Year End 2023 Operating Results Conference Call. At ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-15543 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...